References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

medsovet-9244

Research Article

НОВОСТИ. ОТКРЫТИЯ И СОБЫТИЯ

NEWS, DISCOVERIES AND EVENTS

Колоректальный рак с мутацией BRAF – новый подход к терапии

BRAFV600E-mutant colorectal cancer: A new approach to therapy

редакционная

статья

Editorial

Article

2025

30072025

0101019

2025

редакционная с.

editorial a.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/9244

В России, как и во всем мире, постоянно растет заболеваемость рака толстой и прямой кишки (колоректального рака) – одного из наиболее часто диагностируемых злокачественных новообразований с высоким риском метастазирования и летального исхода. В стране, несмотря на успехи в диагностике этого заболевания на более ранних стадиях, за последние 10 лет отмечается постоянный рост числа пациентов с раком кишечника на 2% и каждый год регистрируется около 75 000 новых случаев. Более 90% пациентов – люди старше 50 лет, но в последние годы отмечается неуклонный рост заболеваемости у более молодых пациентов. Особенно агрессивно колоректальный рак (КРР) протекает при наличии мутаций в гене BRAF.

The prevalence of colon and rectal cancer (colorectal cancer), one of the most commonly diagnosed malignant neoplasms with a high risk of metastasis and death, has been increasing steadily in Russia and throughout the world. Despite advances in the early diagnosis of the disease, there has been a constant increase in the number of patients with bowel cancer by 2% and about 75,000 new cases reported annually in this country over the past ten years. More than 90% of patients are people aged over 50 years, but recent years have witnessed a steady increase in the incidence of the disease among young patients. BRAF-mutated CRC follows an especially aggressive clinical course.

References1

Федянин МЮ, Эльснукаева ХМ, Демидова ИА, Строяковский ДЛ, Шелыгин ЮА, Цуканов АС и др. Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. Результаты многоцентрового исследования. Медицинский совет. 2021;(4S):52–63. https://doi.org/10.21518/2079-701X-2021-4S-52-63.

Fedyanin MY, Ehlsnukaeva КM, Demidova IA, Stroyakovskiy DL, Shelygin YA, Tsukanov АS et al. Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia. Meditsinskiy Sovet. 2021;(4S):52–63. (In Russ.) https://doi.org/10.21518/2079-701X-2021-4S-52-63.

Федянин МЮ, Мамедли ЗЗ, Гордеев СС, Ачкасов СИ, Болотина ЛВ, Гладков ОА и др. Злокачественное новообразование ободочной кишки: клинические рекомендации. 2022. Режим доступа: http://disuria.ru/_ld/12/1281_kr22C18C19MZ.pdf/

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J et al. Electronic address: clinicalguidelines@esmo.org. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003.

Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021;39(4):285–294. https://doi.org/10.1200/JCO.20.01994.

Федянин МЮ, Гладков ОА, Гордеев СС, Карачун АМ, Козлов НА, Мамедли ЗЗ и др. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2024;14(3s2-1):263–322. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-14.

Fedyanin MYU, Gladkov OA, Gordeev SS, Karachun AM, Kozlov NA, Mamedli ZZ et al. Cancer of the colon, rectosigmoid junction and rectum. RUSSCO practical recommendations, part 1.1. Malignant Tumors. 2024;14(3s2-1):263–322. (In Russ.)https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-14.

Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017;28(3):562–568. https://doi.org/10.1093/annonc/mdw645.

Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L et al. Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clin Cancer Res. 2020;26(17):4599–4605. https://doi.org/10.1158/1078-0432.CCR-20-1024.

Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D et al. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022;7(6):100603. https://doi.org/10.1016/j.esmoop.2022.100603.

Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E et al. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600EMutant Metastatic Colorectal Cancer. J Clin Oncol. 2023;41(14):2628–2637. https://doi.org/10.1200/JCO.22.01693.

Andre T, Lenz H, Elez E, Jensen L. First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/ mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. J Clin Onc. 2025;43(4s). https://doi.org/10.1200/JCO.2025.43.4_suppl.LBA143.

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273–284. https://doi.org/10.1200/JCO.20.02088.

NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. National Comprehensive Cancer Network Version 3. 2024. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428.

Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678–700. https://doi.org/10.1200/JCO.22.01690.

Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M et al. BRAF + EGFR +/MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur J Cancer. 2024;210:114290. https://doi.org/10.1016/j.ejca.2024.114290

Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H et al. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study). Clin Colorectal Cancer. 2022;21(4):339–346. https://doi.org/10.1016/j.clcc.2022.08.002.

Sunakawa Yu, Inoue E, Kotani D, Denda T, Inagaki C, Kashiwada T et al. Encorafenib and cetuximab with/without binimetinib therapies for patients with BRAF-mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18). JCO. 2025;43:164–164. https://doi.org/10.1200/JCO.2025.43.4_suppl.164.

Gallois C, Bergen ES, Auclin É, Pernot S, Higué J, Trouilloud I et al. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study. ESMO Open. 2024;9(9):103696. https://doi.org/10.1016/j.esmoop.2024.103696.

Montes AF, Ros J, Graña B, García-Alfonso P, Brozos E, Melian M et al. Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study. J Clin Oncol. 2023;41(4 Suppl.):126–126. https://doi.org/10.1200/JCO.2023.41.4_suppl.126.

The authors declare that there are no conflicts of interest present.